There are a lot of options on the ASX 200 index. But which shares could be good buys this month?
Let's take a look at three that top analysts are recommending as buys. They are as follows:
CSL Ltd (ASX: CSL)
The team at Bell Potter thinks that CSL could be an ASX 200 share to buy. It is the biotechnology giant behind the CSL Behring plasma therapy business, as well as the CSL Seqirus and CSL Vifor businesses.
The broker highlights that CSL is trading at an attractive level for investors, particularly given its positive earnings growth outlook. It said:
CSL presents an attractive buying opportunity as we anticipate the start of a margin recovery phase for CSL, driving above-market earnings growth over the next few years. CSL trades at a 12-month forward PE of ~28x, representing a discount to its 10-year average of ~31x.
Furthermore, the company will continue to deleverage the balance sheet over the next few years. Given the company's proven quality and growth prospects, we believe significant upside remains.
Bell Potter has a buy rating and $345.00 price target on CSL's shares.
Woolworths Group Ltd (ASX: WOW)
Goldman Sachs thinks that Woolworths could be an ASX 200 share to buy this month. It is of course Australia's largest supermarket chain.
The broker likes Woolworths due to its leadership position, omni-channel advantage, and potential to win a significant share of the online grocery market. It explains:
WOW is the largest supermarket chain in Australia. Our Buy thesis is based on 1) robust supermarkets growth of ~4% in FY23-26E driven by strong population growth and a rational, oligopoly environment; 2) omni-channel leader further extending share gains due to its early mover advantage in digitalization and omni-channel execution.
By 2030E, we expect WOW to be the dominant leader in online with ~50% share in a space that is expected to go from 5% to 10% of the total grocery market; 3) loyalty/retail media further margin opportunities: Woolworth's strong digital and omni-channel advantage is further reinforced through a virtuous cycle of loyalty and retail media (Cartology). WOW is also trading below fair value.
Goldman Sachs has a buy rating and $36.20 price target on Woolworths' shares.
ResMed Inc. (ASX: RMD)
Analysts at Catapult Wealth are positive on sleep treatment company ResMed and think it could be an ASX 200 share to buy.
Catapult Wealth's analysts have been pleased with ResMed's performance in FY 2025 and believe there's more to come. Especially given the size of the sleep apnoea market and the low percentage of sufferers getting treatment or even aware of their condition. Its analysts recently told the Bull:
ResMed posted a top first quarter result in fiscal year 2025. Income from operations was up 34 per cent on the prior corresponding period, which was well above previous guidance. Revenue was up 11 per cent. ResMed provides sleep apnoea solutions in a market with strong growth potential.
Awareness and diagnosis of sleep apnoea continues to grow, but only a small percentage of potential patients are receiving treatment. Consequently, this represents a huge opportunity for ResMed. Fears that new weight loss and diabetes drugs would impact the business continue to ease, and, in our view, pose limited risk.
